NVS Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 98.36 |
52 Week High | CHF 120.92 |
52 Week Low | CHF 92.35 |
Beta | 0.51 |
1 Month Change | -5.30% |
3 Month Change | -14.96% |
1 Year Change | 0.99% |
3 Year Change | 14.51% |
5 Year Change | 4.32% |
Change since IPO | 1,035.47% |
Recent News & Updates
Recent updates
Novartis: Time To Increase
Dec 13What To Expect When Novartis Reports Q3 2024 Results
Oct 25Why Novartis Deserves Your Attention After Q2 2024 Results
Jul 19Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
May 27Novartis Looks To Get Back On Track With Q1 Earnings
Apr 19New And Improved Novartis
Oct 30Novartis: Better Margin Visibility Ex-Sandoz
Oct 06Shareholder Returns
NVS | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.6% | -3.3% | -0.4% |
1Y | 1.0% | 10.5% | 27.7% |
Return vs Industry: NVS underperformed the US Pharmaceuticals industry which returned 10.5% over the past year.
Return vs Market: NVS underperformed the US Market which returned 27.7% over the past year.
Price Volatility
NVS volatility | |
---|---|
NVS Average Weekly Movement | 2.2% |
Pharmaceuticals Industry Average Movement | 10.3% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVS's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis AG Fundamentals Summary
NVS fundamental statistics | |
---|---|
Market cap | US$196.45b |
Earnings (TTM) | US$11.76b |
Revenue (TTM) | US$49.94b |
16.7x
P/E Ratio3.9x
P/S RatioIs NVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVS income statement (TTM) | |
---|---|
Revenue | US$49.94b |
Cost of Revenue | US$12.07b |
Gross Profit | US$37.87b |
Other Expenses | US$26.11b |
Earnings | US$11.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) | 5.88 |
Gross Margin | 75.83% |
Net Profit Margin | 23.55% |
Debt/Equity Ratio | 69.8% |
How did NVS perform over the long term?
See historical performance and comparison